Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 571

1.

CGRP-dependent and independent mechanisms of acute and persistent post-traumatic headache following mild traumatic brain injury in mice.

Navratilova E, Rau J, Oyarzo J, Tien J, Mackenzie K, Stratton J, Remeniuk B, Schwedt T, Anderson T, Dodick D, Porreca F.

Cephalalgia. 2019 Sep 24:333102419877662. doi: 10.1177/0333102419877662. [Epub ahead of print]

PMID:
31550910
2.

Post-traumatic headache: epidemiology and pathophysiological insights.

Ashina H, Porreca F, Anderson T, Amin FM, Ashina M, Schytz HW, Dodick DW.

Nat Rev Neurol. 2019 Oct;15(10):607-617. doi: 10.1038/s41582-019-0243-8. Epub 2019 Sep 16. Review.

PMID:
31527806
3.

Antihyperalgesic effects of Meteorin in the rat chronic constriction injury model: a replication study.

Xie JY, Qu C, Munro G, Petersen KA, Porreca F.

Pain. 2019 Aug;160(8):1847-1855. doi: 10.1097/j.pain.0000000000001569.

4.

Cannabinoids induce latent sensitization in a preclinical model of medication overuse headache.

Kopruszinski CM, Navratilova E, Vagnerova B, Swiokla J, Patwardhan A, Dodick D, Porreca F.

Cephalalgia. 2019 Jul 16:333102419865252. doi: 10.1177/0333102419865252. [Epub ahead of print]

PMID:
31311288
5.

Impact of chronic migraine attacks and their severity on the endogenous μ-opioid neurotransmission in the limbic system.

Jassar H, Nascimento TD, Kaciroti N, DosSantos MF, Danciu T, Koeppe RA, Smith YR, Bigal ME, Porreca F, Casey KL, Zubieta JK, DaSilva AF.

Neuroimage Clin. 2019;23:101905. doi: 10.1016/j.nicl.2019.101905. Epub 2019 Jun 18.

6.

Pathophysiology, prevention, and treatment of medication overuse headache.

Diener HC, Dodick D, Evers S, Holle D, Jensen RH, Lipton RB, Porreca F, Silberstein S, Schwedt T.

Lancet Neurol. 2019 Sep;18(9):891-902. doi: 10.1016/S1474-4422(19)30146-2. Epub 2019 Jun 4. Review.

PMID:
31174999
7.

Development and Characterization of An Injury-free Model of Functional Pain in Rats by Exposure to Red Light.

Khanna R, Patwardhan A, Yang X, Li W, Cai S, Ji Y, Chew LA, Dorame A, Bellampalli SS, Schmoll RW, Gordon J, Moutal A, Vanderah TW, Porreca F, Ibrahim MM.

J Pain. 2019 May 2. pii: S1526-5900(18)30814-9. doi: 10.1016/j.jpain.2019.04.008. [Epub ahead of print]

PMID:
31054915
8.

Opioid analgesics pass the acid test.

Navratilova E, Patwardhan A, Porreca F.

Lancet. 2019 Apr 20;393(10181):1579-1581. doi: 10.1016/S0140-6736(19)30421-0. No abstract available.

PMID:
31007186
9.

Antihyperalgesic effects of Meteorin in the rat chronic constriction injury model: a replication study.

Xie JY, Qu C, Munro G, Petersen KA, Porreca F.

Pain. 2019 Apr 11. doi: 10.1097/j.pain.0000000000001569. [Epub ahead of print]

PMID:
30908357
10.

Kappa opioid signaling in the right central amygdala causes hind paw specific loss of diffuse noxious inhibitory controls in experimental neuropathic pain.

Phelps CE, Navratilova E, Dickenson AH, Porreca F, Bannister K.

Pain. 2019 Jul;160(7):1614-1621. doi: 10.1097/j.pain.0000000000001553.

PMID:
30870321
11.

The α2,3-selective potentiator of GABAA receptors, KRM-II-81, reduces nociceptive-associated behaviors induced by formalin and spinal nerve ligation in rats.

Witkin JM, Cerne R, Davis PG, Freeman KB, do Carmo JM, Rowlett JK, Methuku KR, Okun A, Gleason SD, Li X, Krambis MJ, Poe M, Li G, Schkeryantz JM, Jahan R, Yang L, Guo W, Golani LK, Anderson WH, Catlow JT, Jones TM, Porreca F, Smith JL, Knopp KL, Cook JM.

Pharmacol Biochem Behav. 2019 May;180:22-31. doi: 10.1016/j.pbb.2019.02.013. Epub 2019 Feb 27.

PMID:
30825491
12.

Substance P and Inflammatory Pain: Getting It Wrong and Right Simultaneously.

Navratilova E, Porreca F.

Neuron. 2019 Feb 6;101(3):353-355. doi: 10.1016/j.neuron.2019.01.034.

PMID:
30731054
13.

Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140).

Guerrero M, Urbano M, Kim EK, Gamo AM, Riley S, Abgaryan L, Leaf N, Van Orden LJ, Brown SJ, Xie JY, Porreca F, Cameron MD, Rosen H, Roberts E.

J Med Chem. 2019 Feb 28;62(4):1761-1780. doi: 10.1021/acs.jmedchem.8b01679. Epub 2019 Feb 13.

14.

Kappa opioid signaling in the central nucleus of the amygdala promotes disinhibition and aversiveness of chronic neuropathic pain.

Navratilova E, Ji G, Phelps C, Qu C, Hein M, Yakhnitsa V, Neugebauer V, Porreca F.

Pain. 2019 Apr;160(4):824-832. doi: 10.1097/j.pain.0000000000001458.

15.

Sustained exposure to acute migraine medications combined with repeated noxious stimulation dysregulates descending pain modulatory circuits: Relevance to medication overuse headache.

Nation KM, Dodick DW, Navratilova E, Porreca F.

Cephalalgia. 2019 Apr;39(5):617-625. doi: 10.1177/0333102418804157. Epub 2018 Oct 4.

PMID:
30286616
16.

Kappa Opioid Receptor Distribution and Function in Primary Afferents.

Snyder LM, Chiang MC, Loeza-Alcocer E, Omori Y, Hachisuka J, Sheahan TD, Gale JR, Adelman PC, Sypek EI, Fulton SA, Friedman RL, Wright MC, Duque MG, Lee YS, Hu Z, Huang H, Cai X, Meerschaert KA, Nagarajan V, Hirai T, Scherrer G, Kaplan DH, Porreca F, Davis BM, Gold MS, Koerber HR, Ross SE.

Neuron. 2018 Sep 19;99(6):1274-1288.e6. doi: 10.1016/j.neuron.2018.08.044.

17.

Positive allosteric modulators of nonbenzodiazepine γ-aminobutyric acidA receptor subtypes for the treatment of chronic pain.

Johnstone TBC, Xie JY, Qu C, Wasiak DJ, Hogenkamp DJ, Porreca F, Gee KW.

Pain. 2019 Jan;160(1):198-209. doi: 10.1097/j.pain.0000000000001392.

PMID:
30204648
18.

The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia.

Flores AJ, Bartlett MJ, Root BK, Parent KL, Heien ML, Porreca F, Polt R, Sherman SJ, Falk T.

Neuropharmacology. 2018 Oct;141:260-271. doi: 10.1016/j.neuropharm.2018.09.005. Epub 2018 Sep 7.

19.

Inhibition of experimental visceral pain in rodents by cebranopadol.

Schiene K, Schröder W, Linz K, Frosch S, Tzschentke TM, Christoph T, Xie JY, Porreca F.

Behav Pharmacol. 2019 Jun;30(4):320-326. doi: 10.1097/FBP.0000000000000420.

PMID:
30161034
20.

Morphine effects within the rodent anterior cingulate cortex and rostral ventromedial medulla reveal separable modulation of affective and sensory qualities of acute or chronic pain.

Gomtsian L, Bannister K, Eyde N, Robles D, Dickenson AH, Porreca F, Navratilova E.

Pain. 2018 Dec;159(12):2512-2521. doi: 10.1097/j.pain.0000000000001355.

PMID:
30086115
21.

Representations of Syrian food by Syrian refugees in the city of São Paulo, Brazil: An ethnographic study.

Scagliusi FB, Porreca FI, Ulian MD, de Morais Sato P, Unsain RF.

Appetite. 2018 Oct 1;129:236-244. doi: 10.1016/j.appet.2018.07.014. Epub 2018 Jul 17.

PMID:
30030138
22.

In Reply.

Garami A, Ibrahim M, Gilbraith K, Khanna R, Pakai E, Miko A, Pinter E, Romanovsky AA, Porreca F, Patwardhan AM.

Anesthesiology. 2018 Aug;129(2):378-379. doi: 10.1097/ALN.0000000000002294. No abstract available.

PMID:
30020181
23.

Selective deficiencies in descending inhibitory modulation in neuropathic rats: implications for enhancing noradrenergic tone.

Patel R, Qu C, Xie JY, Porreca F, Dickenson AH.

Pain. 2018 Sep;159(9):1887-1899. doi: 10.1097/j.pain.0000000000001300.

24.

Cyclic biphalin analogues with a novel linker lead to potent agonist activities at mu, delta, and kappa opioid receptors.

Remesic M, Macedonio G, Mollica A, Porreca F, Hruby V, Lee YS.

Bioorg Med Chem. 2018 Jul 23;26(12):3664-3667. doi: 10.1016/j.bmc.2018.05.045. Epub 2018 May 26.

PMID:
29858157
25.

The opioid crisis and … reconsidering the use of drugs that affect body temperature.

Patwardhan A, Porreca F, Schmidt WK, Romanovsky AA.

Temperature (Austin). 2018 Mar 6;5(1):1-3. doi: 10.1080/23328940.2018.1437312. eCollection 2018. No abstract available.

26.

Chronic pain impairs cognitive flexibility and engages novel learning strategies in rats.

Cowen SL, Phelps CE, Navratilova E, McKinzie DL, Okun A, Husain O, Gleason SD, Witkin JM, Porreca F.

Pain. 2018 Jul;159(7):1403-1412. doi: 10.1097/j.pain.0000000000001226.

27.

Lateralized kappa opioid receptor signaling from the amygdala central nucleus promotes stress-induced functional pain.

Nation KM, De Felice M, Hernandez PI, Dodick DW, Neugebauer V, Navratilova E, Porreca F.

Pain. 2018 May;159(5):919-928. doi: 10.1097/j.pain.0000000000001167.

28.

Activation of ventral tegmental area dopaminergic neurons reverses pathological allodynia resulting from nerve injury or bone cancer.

Watanabe M, Narita M, Hamada Y, Yamashita A, Tamura H, Ikegami D, Kondo T, Shinzato T, Shimizu T, Fukuchi Y, Muto A, Okano H, Yamanaka A, Tawfik VL, Kuzumaki N, Navratilova E, Porreca F, Narita M.

Mol Pain. 2018 Jan-Dec;14:1744806918756406. doi: 10.1177/1744806918756406. Epub 2018 Jan 22.

29.

Extracellular N-acetylaspartylglutamate released in the nucleus accumbens modulates the pain sensation: Analysis using a microdialysis/mass spectrometry integrated system.

Watanabe M, Sugiura Y, Sugiyama E, Narita M, Navratilova E, Kondo T, Uchiyama N, Yamanaka A, Kuzumaki N, Porreca F, Narita M.

Mol Pain. 2018 Jan-Dec;14:1744806918754934. doi: 10.1177/1744806918754934. Epub 2018 Jan 8.

30.

Disease modifying actions of interleukin-6 blockade in a rat model of bone cancer pain.

Remeniuk B, King T, Sukhtankar D, Nippert A, Li N, Li F, Cheng K, Rice KC, Porreca F.

Pain. 2018 Apr;159(4):684-698. doi: 10.1097/j.pain.0000000000001139.

31.

Nanoparticulate peptide delivery exclusively to the brain produces tolerance free analgesia.

Godfrey L, Iannitelli A, Garrett NL, Moger J, Imbert I, King T, Porreca F, Soundararajan R, Lalatsa A, Schätzlein AG, Uchegbu IF.

J Control Release. 2018 Jan 28;270:135-144. doi: 10.1016/j.jconrel.2017.11.041. Epub 2017 Nov 27.

32.

Multiple sites and actions of gabapentin-induced relief of ongoing experimental neuropathic pain.

Bannister K, Qu C, Navratilova E, Oyarzo J, Xie JY, King T, Dickenson AH, Porreca F.

Pain. 2017 Dec;158(12):2386-2395. doi: 10.1097/j.pain.0000000000001040.

33.

Synthesis and Investigation of Mixed μ-Opioid and δ-Opioid Agonists as Possible Bivalent Ligands for Treatment of Pain.

Vardanyan RS, Cain JP, Haghighi SM, Kumirov VK, McIntosh MI, Sandweiss AJ, Porreca F, Hruby VJ.

J Heterocycl Chem. 2017 Mar;54(2):1228-1235. doi: 10.1002/jhet.2696. Epub 2016 Jun 1.

34.

CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide.

Moutal A, Yang X, Li W, Gilbraith KB, Luo S, Cai S, François-Moutal L, Chew LA, Yeon SK, Bellampalli SS, Qu C, Xie JY, Ibrahim MM, Khanna M, Park KD, Porreca F, Khanna R.

Pain. 2017 Dec;158(12):2301-2319. doi: 10.1097/j.pain.0000000000001002.

35.

Transient Receptor Potential Vanilloid 1 Antagonists Prevent Anesthesia-induced Hypothermia and Decrease Postincisional Opioid Dose Requirements in Rodents.

Garami A, Ibrahim M, Gilbraith K, Khanna R, Pakai E, Miko A, Pinter E, Romanovsky AA, Porreca F, Patwardhan AM.

Anesthesiology. 2017 Nov;127(5):813-823. doi: 10.1097/ALN.0000000000001812.

PMID:
28806222
36.

Mechanisms of craniofacial pain.

Chichorro JG, Porreca F, Sessle B.

Cephalalgia. 2017 Jun;37(7):613-626. doi: 10.1177/0333102417704187. Epub 2017 Apr 25. Review.

PMID:
28440673
37.

Mediation of Movement-Induced Breakthrough Cancer Pain by IB4-Binding Nociceptors in Rats.

Havelin J, Imbert I, Sukhtankar D, Remeniuk B, Pelletier I, Gentry J, Okun A, Tiutan T, Porreca F, King TE.

J Neurosci. 2017 May 17;37(20):5111-5122. doi: 10.1523/JNEUROSCI.1212-16.2017. Epub 2017 Apr 24.

38.

Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention.

Xie JY, De Felice M, Kopruszinski CM, Eyde N, LaVigne J, Remeniuk B, Hernandez P, Yue X, Goshima N, Ossipov M, King T, Streicher JM, Navratilova E, Dodick D, Rosen H, Roberts E, Porreca F.

Cephalalgia. 2017 Jul;37(8):780-794. doi: 10.1177/0333102417702120. Epub 2017 Apr 4.

39.

Recent Advances in the Realm of Allosteric Modulators for Opioid Receptors for Future Therapeutics.

Remesic M, Hruby VJ, Porreca F, Lee YS.

ACS Chem Neurosci. 2017 Jun 21;8(6):1147-1158. doi: 10.1021/acschemneuro.7b00090. Epub 2017 Apr 7. Review.

40.

Reward, motivation, and emotion of pain and its relief.

Porreca F, Navratilova E.

Pain. 2017 Apr;158 Suppl 1:S43-S49. doi: 10.1097/j.pain.0000000000000798. Review. No abstract available.

41.

Long-lasting antinociceptive effects of green light in acute and chronic pain in rats.

Ibrahim MM, Patwardhan A, Gilbraith KB, Moutal A, Yang X, Chew LA, Largent-Milnes T, Malan TP, Vanderah TW, Porreca F, Khanna R.

Pain. 2017 Feb;158(2):347-360. doi: 10.1097/j.pain.0000000000000767.

42.

Efficacy of (S)-Lacosamide in preclinical models of cephalic pain.

Moutal A, Eyde N, Telemi E, Park KD, Xie JY, Dodick DW, Porreca F, Khanna R.

Pain Rep. 2016 Jun;1(1). pii: e565.

43.

Anatomy and immunochemical characterization of the non-arterial peptidergic diffuse dural innervation of the rat and Rhesus monkey: Implications for functional regulation and treatment in migraine.

Rice FL, Xie JY, Albrecht PJ, Acker E, Bourgeois J, Navratilova E, Dodick DW, Porreca F.

Cephalalgia. 2017 Dec;37(14):1350-1372. doi: 10.1177/0333102416677051. Epub 2016 Nov 16.

PMID:
27852962
44.

Structure-Activity Relationships of [des-Arg7]Dynorphin A Analogues at the κ Opioid Receptor.

Ramos-Colon CN, Lee YS, Remesic M, Hall SM, LaVigne J, Davis P, Sandweiss AJ, McIntosh MI, Hanson J, Largent-Milnes TM, Vanderah TW, Streicher J, Porreca F, Hruby VJ.

J Med Chem. 2016 Nov 23;59(22):10291-10298. Epub 2016 Nov 8.

45.

Cyclic non-opioid dynorphin A analogues for the bradykinin receptors.

Lee YS, Remesic M, Ramos-Colon C, Hall SM, Kuzmin A, Rankin D, Porreca F, Lai J, Hruby VJ.

Bioorg Med Chem Lett. 2016 Nov 15;26(22):5513-5516. doi: 10.1016/j.bmcl.2016.10.010. Epub 2016 Oct 6.

46.

Discovery of Stable Non-opioid Dynorphin A Analogues Interacting at the Bradykinin Receptors for the Treatment of Neuropathic Pain.

Hall SM, LeBaron L, Ramos-Colon C, Qu C, Xie JY, Porreca F, Lai J, Lee YS, Hruby VJ.

ACS Chem Neurosci. 2016 Dec 21;7(12):1746-1752. doi: 10.1021/acschemneuro.6b00258. Epub 2016 Sep 27.

47.

Hedonic and motivational responses to food reward are unchanged in rats with neuropathic pain.

Okun A, McKinzie DL, Witkin JM, Remeniuk B, Husein O, Gleason SD, Oyarzo J, Navratilova E, McElroy B, Cowen S, Kennedy JD, Porreca F.

Pain. 2016 Dec;157(12):2731-2738.

48.

Sustained relief of ongoing experimental neuropathic pain by a CRMP2 peptide aptamer with low abuse potential.

Xie JY, Chew LA, Yang X, Wang Y, Qu C, Wang Y, Federici LM, Fitz SD, Ripsch MS, Due MR, Moutal A, Khanna M, White FA, Vanderah TW, Johnson PL, Porreca F, Khanna R.

Pain. 2016 Sep;157(9):2124-40. doi: 10.1097/j.pain.0000000000000628.

49.

Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents.

Kopruszinski CM, Xie JY, Eyde NM, Remeniuk B, Walter S, Stratton J, Bigal M, Chichorro JG, Dodick D, Porreca F.

Cephalalgia. 2017 May;37(6):560-570. doi: 10.1177/0333102416650702. Epub 2016 May 19.

PMID:
27206958
50.

Various modifications of the amphipathic dynorphin A pharmacophore for rat brain bradykinin receptors.

Lee YS, Kupp R, Remesic MV, Ramos-Colon C, Hall SM, Chan C, Rankin D, Lai J, Porreca F, Hruby VJ.

Chem Biol Drug Des. 2016 Oct;88(4):615-9. doi: 10.1111/cbdd.12789. Epub 2016 Jun 6.

Supplemental Content

Loading ...
Support Center